DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT02527421
- Locations
- 🇺🇸
Site 102, Encino, California, United States
🇺🇸Site 101, Houston, Texas, United States
🇺🇸Site 104, Irvine, California, United States
Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers
- First Posted Date
- 2015-02-11
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Primus Pharmaceuticals
- Registration Number
- NCT02361437
- Locations
- 🇺🇸
Nix Hospital, San Antonio, Texas, United States
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT02070965
- Locations
- 🇺🇸
California Dermatology and Clinical Research Institute, Encinitas, California, United States
🇺🇸Redwood Dermatology Research, Santa Rosa, California, United States
🇺🇸Dermatology Consulting Services, High Point, North Carolina, United States
A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 277
- Registration Number
- NCT01967069
- Locations
- 🇺🇸
Hudson Dermatology/Clinical Research Advantage, Tempe, Arizona, United States
🇺🇸Augusta Centre for Dermatology and Skin Renewal, LLC, Augusta, Georgia, United States
🇺🇸Grekin Skin Institute, Warren, Michigan, United States
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 394
- Registration Number
- NCT01947491
- Locations
- 🇺🇸
Rivergate Dermatology Clinical Research Center, PLLC, Goodlettsville, Tennessee, United States
🇺🇸The Center for Skin Research, Houston, Texas, United States
🇺🇸Skin Surgery Medical Group, Inc., San Diego, California, United States
Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
- Conditions
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT00928837
- Locations
- 🇺🇸
Alan Kivitz MD, Duncansville, Pennsylvania, United States
Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee
- Conditions
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 223
- Registration Number
- NCT00790985
Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee
- Conditions
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT00435292
- Locations
- 🇺🇸
Primus Pharmaceuticals, Inc, Scottsdale, Arizona, United States
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00303017
- Locations
- 🇺🇸
Timothy Truitt MD, Melbourne, Florida, United States